Document 0521
 DOCN  M9480521
 TI    Binding of human immunodeficiency virus type 1 to the C3b/C4b receptor
       CR1 (CD35) and red blood cells in the presence of envelope-specific
       antibodies and complement. National Institutes of Health AIDS Vaccine
       Clinical Trials Networks.
 DT    9410
 AU    Montefiori DC; Graham BS; Zhou JY; Zhou JT; Ahearn JM; Dept. of Surgery,
       Duke University Medical Center, Durham, NC; 27710.
 SO    J Infect Dis. 1994 Aug;170(2):429-32. Unique Identifier : AIDSLINE
       MED/94308613
 AB    Immune complexes formed in vitro by incubating cell-free human
       immunodeficiency virus type 1 (HIV-1) with sera from infected or
       gp160-vaccinated persons, together with normal human serum as a source
       of complement, readily bound to K562 cells expressing recombinant human
       complement receptor type 1 (CR1). However, antibodies from seronegative
       persons had little or no effect. This effect was absent in the presence
       of heat-inactivated or C3-depleted normal human sera or when wild type
       K562 cells were used, confirming a requirement for complement and CR1.
       In additional experiments, complement alone targeted HIV-1 to CR1 on red
       blood cells, and envelope-specific antibodies increased this effect.
       These results demonstrate that envelope-specific antibodies promote
       HIV-1 immune complex formation with complement and that these complexes
       readily bind CR1 on cell surfaces.
 DE    Antigen-Antibody Complex/METABOLISM  Complement/*IMMUNOLOGY  Complement
       Activation  Erythrocytes/*METABOLISM  Gene Products, env/IMMUNOLOGY
       Human  HIV Antibodies/*IMMUNOLOGY  HIV-1/IMMUNOLOGY/*METABOLISM  Immune
       Sera/IMMUNOLOGY  Protein Precursors/IMMUNOLOGY  Receptors, Complement
       3b/*METABOLISM  Support, U.S. Gov't, P.H.S.  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).